Vivani Medical Insider Buys $1.98mln Worth of Shares, According to SEC Filing

Vivani Medical has disclosed that an insider bought shares worth $1,983,333 according to a recent SEC filing. The biopharmaceutical company is developing ultra-long-acting drug implants using its NanoPortal platform for treatments such as chronic weight management and Type II diabetes. The company's lead program, NPM-115, is a six-month subdermal implant for obesity treatment.

Eikon Therapeutics, a late-stage clinical biopharmaceutical company, has announced, in a BioSpace press release, that new data from its Phase 2 study of EIK1001 will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Berlin, Germany from October 17-21, 2025. The study, titled "TeLuRide-005: Phase II study of EIK1001, a toll-like receptor 7/8 (TLR7/8) co-agonist with pembrolizumab (pembro)+chemotherapy (chemo) as first-line (1L) therapy in stage 4 non-small cell lung cancer (NSCLC)," will be presented by Dr. Richard J. Gralla during the Mini Oral Session 2 on Monday, October 20 at 10:55 AM CEST.

EIK1001 is a TLR7/8 co-agonist designed to enhance T-cell recognition and tumor killing, potentially overcoming immune resistance observed in advanced NSCLC. The molecule is being studied in combination with pembrolizumab and histology-appropriate chemotherapy in patients with Stage 4 NSCLC. The trial’s primary objective is to evaluate the safety and tolerability of EIK1001 in the triplet combination. Additionally, Eikon hopes to explore whether the immunomodulatory mechanism of EIK1001 might improve lung cancer treatment regimens.

Eikon Therapeutics is also advancing a portfolio of differentiated oncology programs, including EIK1003-001 and EIK1004-001, which are PARP1 inhibitors, and EIK1005, a novel program targeting Werner (WRN) helicase for microsatellite unstable cancers and sensitive cancers with other defects in DNA repair, the press release noted.